KEROS THERAPEUTICS INC (KROS) Stock Fundamental Analysis
NASDAQ:KROS • US4923271013
16.2 USD
-0.35 (-2.11%)
At close: Feb 20, 2026
16.2 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Taking everything into account, KROS scores 5 out of 10 in our fundamental rating. KROS was compared to 521 industry peers in the Biotechnology industry. KROS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KROS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year KROS was profitable.
- In the past year KROS had a positive cash flow from operations.
- In the past 5 years KROS always reported negative net income.
- KROS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- KROS has a Return On Assets of 8.68%. This is amongst the best in the industry. KROS outperforms 93.28% of its industry peers.
- The Return On Equity of KROS (9.16%) is better than 92.90% of its industry peers.
- KROS has a better Return On Invested Capital (4.79%) than 91.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 9.16% | ||
| ROIC | 4.79% |
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- KROS's Profit Margin of 26.12% is amongst the best of the industry. KROS outperforms 95.20% of its industry peers.
- Looking at the Operating Margin, with a value of 17.67%, KROS belongs to the top of the industry, outperforming 93.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.67% | ||
| PM (TTM) | 26.12% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- KROS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- KROS has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, KROS has more shares outstanding
- KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 8.50 indicates that KROS is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 8.50, KROS is in the better half of the industry, outperforming 79.46% of the companies in the same industry.
- There is no outstanding debt for KROS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.5 |
ROIC/WACC0.55
WACC8.72%
2.3 Liquidity
- KROS has a Current Ratio of 29.86. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
- KROS has a better Current ratio (29.86) than 97.89% of its industry peers.
- KROS has a Quick Ratio of 29.86. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 29.86, KROS belongs to the best of the industry, outperforming 97.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 29.86 | ||
| Quick Ratio | 29.86 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 129.56% over the past year.
- The Revenue has grown by 37798.31% in the past year. This is a very strong growth!
- KROS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.71% yearly.
EPS 1Y (TTM)129.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.23%
Revenue 1Y (TTM)37798.31%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%3575.77%
3.2 Future
- The Earnings Per Share is expected to grow by 7.68% on average over the next years.
- Based on estimates for the next years, KROS will show a very strong growth in Revenue. The Revenue will grow by 166.06% on average per year.
EPS Next Y143.7%
EPS Next 2Y15.78%
EPS Next 3Y8.49%
EPS Next 5Y7.68%
Revenue Next Year40853.1%
Revenue Next 2Y384.99%
Revenue Next 3Y139.88%
Revenue Next 5Y166.06%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 10.52, the valuation of KROS can be described as reasonable.
- KROS's Price/Earnings ratio is rather cheap when compared to the industry. KROS is cheaper than 97.89% of the companies in the same industry.
- KROS's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.99.
- The Forward Price/Earnings Ratio is negative for KROS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.52 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 100.00% of the companies in the same industry are more expensive than KROS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.67 | ||
| EV/EBITDA | -4.2 |
4.3 Compensation for Growth
- KROS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y15.78%
EPS Next 3Y8.49%
5. Dividend
5.1 Amount
- No dividends for KROS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
16.2
-0.35 (-2.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners105.66%
Inst Owner Change-10.34%
Ins Owners1.65%
Ins Owner Change3.24%
Market Cap493.61M
Revenue(TTM)246.72M
Net Income(TTM)64.45M
Analysts80
Price Target23.97 (47.96%)
Short Float %7.98%
Short Ratio4.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.66%
Min EPS beat(2)34.17%
Max EPS beat(2)83.15%
EPS beat(4)3
Avg EPS beat(4)416.03%
Min EPS beat(4)-13.69%
Max EPS beat(4)1560.5%
EPS beat(8)6
Avg EPS beat(8)209.12%
EPS beat(12)9
Avg EPS beat(12)139.65%
EPS beat(16)11
Avg EPS beat(16)109.44%
Revenue beat(2)2
Avg Revenue beat(2)405.88%
Min Revenue beat(2)267.96%
Max Revenue beat(2)543.8%
Revenue beat(4)3
Avg Revenue beat(4)2529.19%
Min Revenue beat(4)-80.66%
Max Revenue beat(4)9385.68%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.53%
PT rev (3m)2.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.29%
EPS NY rev (1m)0%
EPS NY rev (3m)140.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.52 | ||
| Fwd PE | N/A | ||
| P/S | 2 | ||
| P/FCF | 5.67 | ||
| P/OCF | 5.56 | ||
| P/B | 0.7 | ||
| P/tB | 0.7 | ||
| EV/EBITDA | -4.2 |
EPS(TTM)1.54
EY9.51%
EPS(NY)-3.3
Fwd EYN/A
FCF(TTM)2.86
FCFY17.64%
OCF(TTM)2.91
OCFY17.99%
SpS8.1
BVpS23.09
TBVpS23.09
PEG (NY)0.07
PEG (5Y)N/A
Graham Number28.29
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 9.16% | ||
| ROCE | 6.06% | ||
| ROIC | 4.79% | ||
| ROICexc | 136.53% | ||
| ROICexgc | 136.53% | ||
| OM | 17.67% | ||
| PM (TTM) | 26.12% | ||
| GM | N/A | ||
| FCFM | 35.3% |
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 118.39% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 197.2% | ||
| Profit Quality | 135.12% | ||
| Current Ratio | 29.86 | ||
| Quick Ratio | 29.86 | ||
| Altman-Z | 8.5 |
F-Score8
WACC8.72%
ROIC/WACC0.55
Cap/Depr(3y)214.84%
Cap/Depr(5y)203.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)129.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.23%
EPS Next Y143.7%
EPS Next 2Y15.78%
EPS Next 3Y8.49%
EPS Next 5Y7.68%
Revenue 1Y (TTM)37798.31%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%3575.77%
Revenue Next Year40853.1%
Revenue Next 2Y384.99%
Revenue Next 3Y139.88%
Revenue Next 5Y166.06%
EBIT growth 1Y121.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.19%
EBIT Next 3Y16.61%
EBIT Next 5YN/A
FCF growth 1Y170.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y173.69%
OCF growth 3YN/A
OCF growth 5YN/A
KEROS THERAPEUTICS INC / KROS FAQ
What is the fundamental rating for KROS stock?
ChartMill assigns a fundamental rating of 5 / 10 to KROS.
What is the valuation status for KROS stock?
ChartMill assigns a valuation rating of 5 / 10 to KEROS THERAPEUTICS INC (KROS). This can be considered as Fairly Valued.
What is the profitability of KROS stock?
KEROS THERAPEUTICS INC (KROS) has a profitability rating of 4 / 10.
How financially healthy is KEROS THERAPEUTICS INC?
The financial health rating of KEROS THERAPEUTICS INC (KROS) is 8 / 10.